JAK-inhibitors: clinical pharmacology and application perspectives

Svetlana A. Doktorova, V. Rafalskiy, Y. Y. Grabovetskaya, S. Korenev
{"title":"JAK-inhibitors: clinical pharmacology and application perspectives","authors":"Svetlana A. Doktorova, V. Rafalskiy, Y. Y. Grabovetskaya, S. Korenev","doi":"10.17816/rcf204421-434","DOIUrl":null,"url":null,"abstract":"BACKGROUND: For the last decade, physicians and researchers have been actively developing and investigating a novel targeted synthetic disease-modifying antirheumatic drugs. The application of drugs that affect the JAK-STAT pathway and multiple proinflammatory cytokines certainly has great potential for the treatment of different inflammatory diseases. This review provides articles from the past 10 years describing these small-molecule inhibitors: clinical pharmacology, safety, adverse effects and application. There is a growing body of literature that recognises the importance of JAK inhibitors as attractive pharmacological alternative to biologics. \nAIM: The article aims to explore clinical pharmacology of JAK inhibitors, safety, drug interactions, comparison with biologic disease-modifying antirheumatic drugs and perspective applications for these drugs. \nMATERIALS AND METHODS: The research data in this review is drawn from five main sources: PubMed, Scopus, Medline, GoogleScholar, eLibrary. A search was conducted for the period from 2012 to 2022 in Russian and English, by combinations of words: janus kinase inhibitors, disease-modifying antirheumatic drugs, safety, adverse effects, autoimmune diseases, pharmacokinetics, pharmacodynamics. \nRESULTS: The most important clinically relevant findings were that these small-molecule inhibitors have a main advantages like oral administration, rapid therapeutics effect and less of patients-non-responders to therapy. On the other hand, JAK inhibitors have a classic pharmacokinetics and pharmacodynamics, this allows to study such parameters using standard methods. \nCONCLUSIONS: In this review, the aim was to assess clinical pharmacology of JAK inhibitors, safety, comparison withbiologic disease-modifying antirheumatic drugs and perspective applications for these drugs. In general, it seems that the safety issues of JAK inhibitors unresolved, in particular the development of thromboembolic complications, infectiousdiseases, and malignancies. This is an important issue for future research.","PeriodicalId":21186,"journal":{"name":"Reviews on Clinical Pharmacology and Drug Therapy","volume":"101 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on Clinical Pharmacology and Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17816/rcf204421-434","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND: For the last decade, physicians and researchers have been actively developing and investigating a novel targeted synthetic disease-modifying antirheumatic drugs. The application of drugs that affect the JAK-STAT pathway and multiple proinflammatory cytokines certainly has great potential for the treatment of different inflammatory diseases. This review provides articles from the past 10 years describing these small-molecule inhibitors: clinical pharmacology, safety, adverse effects and application. There is a growing body of literature that recognises the importance of JAK inhibitors as attractive pharmacological alternative to biologics. AIM: The article aims to explore clinical pharmacology of JAK inhibitors, safety, drug interactions, comparison with biologic disease-modifying antirheumatic drugs and perspective applications for these drugs. MATERIALS AND METHODS: The research data in this review is drawn from five main sources: PubMed, Scopus, Medline, GoogleScholar, eLibrary. A search was conducted for the period from 2012 to 2022 in Russian and English, by combinations of words: janus kinase inhibitors, disease-modifying antirheumatic drugs, safety, adverse effects, autoimmune diseases, pharmacokinetics, pharmacodynamics. RESULTS: The most important clinically relevant findings were that these small-molecule inhibitors have a main advantages like oral administration, rapid therapeutics effect and less of patients-non-responders to therapy. On the other hand, JAK inhibitors have a classic pharmacokinetics and pharmacodynamics, this allows to study such parameters using standard methods. CONCLUSIONS: In this review, the aim was to assess clinical pharmacology of JAK inhibitors, safety, comparison withbiologic disease-modifying antirheumatic drugs and perspective applications for these drugs. In general, it seems that the safety issues of JAK inhibitors unresolved, in particular the development of thromboembolic complications, infectiousdiseases, and malignancies. This is an important issue for future research.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
jak -抑制剂:临床药理学及应用前景
背景:在过去的十年中,医生和研究人员一直在积极开发和研究一种新的靶向合成疾病改善抗风湿药物。影响JAK-STAT通路和多种促炎细胞因子的药物的应用对于治疗不同的炎性疾病具有很大的潜力。本文综述了近10年来小分子抑制剂的临床药理学、安全性、不良反应和应用。越来越多的文献认识到JAK抑制剂作为生物制剂的有吸引力的药理替代品的重要性。目的:探讨JAK抑制剂的临床药理学、安全性、药物相互作用、与生物减病抗风湿药物的比较及其应用前景。材料和方法:本综述中的研究数据来自五个主要来源:PubMed, Scopus, Medline, GoogleScholar, library。对2012年至2022年期间的俄语和英语进行了检索,检索词组合为:janus激酶抑制剂、改善疾病的抗风湿药物、安全性、不良反应、自身免疫性疾病、药代动力学、药效学。结果:最重要的临床相关发现是这些小分子抑制剂具有口服给药、治疗效果快、患者对治疗无反应少等主要优势。另一方面,JAK抑制剂具有经典的药代动力学和药效学,因此可以使用标准方法研究这些参数。结论:本综述旨在评价JAK抑制剂的临床药理学、安全性、与生物减病抗风湿药物的比较以及这些药物的应用前景。总的来说,JAK抑制剂的安全性问题似乎尚未解决,特别是血栓栓塞并发症、传染病和恶性肿瘤的发展。这是今后研究的一个重要问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
期刊最新文献
KISS1 KISSPEPTIN OF BONY FISH AND MAMMALIAN KISSPEPTIN ANALOGUES ENHANCE COMMUNICATIVE BEHAVIOUR OF DANIO RERIO INDUCED BY SOCIAL ISOLATION Modern view on the effectiveness and safety of non-steroidal anti-inflammatory drugs Influence of gel matrix on wound healing activity of adhesive dressings filled with silver nanoparticles and humic acids applied for the rat burn model. EARLY STRESS OF MATERNAL DEPRIVATION AFFECTS THE EXPRESSION OF OX1R OREXIN IN THE LIMBIC SYSTEM OF THE BRAIN AND CONTRIBUTES TO THE DEVELOPMENT OF ANXIETY-DEPRESSIVE SYMPTOMS IN RATS. INVOLVEMENT OF BDNF, NTRK2 AND PI3K IN THE MECHANISMS OF BINGE EATING AFTER PSYCHOGENIC STRESSORS IN ONTOGENESIS
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1